Treatment of colorectal liver metastases (Q59267675)

Europe PubMed Central

21 March 2019

Europe PubMed Central

on focus list of Wikimedia project

3 April 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1477-7819-9-154

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Trends in long-term survival following liver resection for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Hepatic arterial infusion after liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Histological assessment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Epidemiology and natural history of NAFLD and NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Impact of steatosis on perioperative outcome following hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Steatosis as a risk factor in liver surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

The EGF receptor is required for efficient liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Effect of molecular therapeutics on liver regeneration in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-9-154

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

21 January 2018

1 reference

12 December 2020

Resection of colorectal liver metastases

1 reference

12 December 2020

Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive

1 reference

12 December 2020

Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie

1 reference

12 December 2020

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial

1 reference

12 December 2020

Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases

1 reference

12 December 2020

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Prevalence of and risk factors for hepatic steatosis in Northern Italy

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Moving beyond fluorouracil for colorectal cancer

1 reference

12 December 2020

Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma.

1 reference

12 December 2020

[When is first-line resection of hepatic metastasis indicated?]

1 reference

12 December 2020

Liver resection for colorectal metastases

1 reference

12 December 2020

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study

1 reference

12 December 2020

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

1 reference

12 December 2020

Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome

1 reference

12 December 2020

Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.

1 reference

12 December 2020

Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases

1 reference

12 December 2020

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

1 reference

12 December 2020

Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020